middle.news
How Nyrada Navigated ASX Scrutiny to Confirm Xolatryp Safety
9:52am on Thursday 14th of August, 2025 AEST
•
Healthcare
Read Story
How Nyrada Navigated ASX Scrutiny to Confirm Xolatryp Safety
9:52am on Thursday 14th of August, 2025 AEST
Key Points
Nyrada confirms positive safety review of Xolatryp Phase I trial cohort six
Safety Review Committee found no safety concerns or serious adverse events
Company clarified timeline of awareness and immediate disclosure on 6 August 2025
Nyrada affirmed compliance with ASX Listing Rule 3.1 and continuous disclosure obligations
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nyrada (ASX:NYR)
OPEN ARTICLE